GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Lexeo Therapeutics
Lexeo Therapeutics, a gene therapy company, is a venture bet on a breakthrough in the treatment of rare diseases. Its price reflects investors' faith in the potential of its scientific platform and clinical trial results, not current revenue.
Share prices of companies in the market segment - Dna
Lexeo Therapeutics (LXEO) is a clinical-stage biotechnology company focused on developing gene therapies for the treatment of rare genetic cardiovascular and neurodegenerative diseases. We classify it as a "DNA technology company." The chart below illustrates the dynamics of this cutting-edge biotech sector.
Broad Market Index - GURU.Markets
Lexeo Therapeutics is a biotech company developing gene therapies for rare cardiovascular and neurological diseases. As a component of the GURU.Markets index, it represents the cutting edge of medicine. The chart below represents the entire market. See how this innovator compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
LXEO - Daily change in the company's share price Lexeo Therapeutics
Shares of Lexeo, a gene therapy company, are extremely volatile. Change_co measures the market's reaction to clinical trial data. This metric is an essential component for building valuation models for companies at the forefront of genetics on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Dna
Lexeo Therapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with LXEO, which focuses on gene therapy, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Lexeo is a biopharmaceutical company specializing in gene therapy. This is a cutting-edge and highly speculative area of biotech. The chart below illustrates the high volatility typical of this sector, reflecting the risks and potential associated with Lexeo's technology.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Lexeo Therapeutics
Lexeo Therapeutics' year-over-year performance is a story of gene therapy development for rare cardiovascular and neurological diseases. Its 12-month market cap depends entirely on progress in clinical trials. Every successful step confirms the potential of its platform and brings treatment for devastating diseases closer.
Annual dynamics of market capitalization of the market segment - Dna
Lexeo Therapeutics, a recent IPO, is a biotech company developing gene therapies. Its performance reflects investor confidence in its scientific platform. The chart below shows how its high potential and early-stage risks compare to a sector dominated by giants.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Lexeo Therapeutics is a clinical-stage biotech whose fate since its IPO has depended on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new gene therapy trials. The company's stock chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Lexeo Therapeutics
As a gene therapy company, Lexeo's performance will be speculative. Monthly fluctuations on the chart will reflect not revenue, but rather news about the progress of clinical trials of its drugs for cardiovascular and neurological diseases, which will determine its future.
Monthly dynamics of market capitalization of the market segment - Dna
Gene therapy is at the cutting edge of medicine, where companies are evaluated based on the potential of their scientific platform. The dynamics of this biotech sector, reflected in the chart, reveal a high degree of speculative interest and volatility. Companies like Lexeo Therapeutics are at the forefront of this field.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Lexeo Therapeutics is a biotech company developing gene therapy. Its shares are driven by scientific discoveries and clinical data. Their price can fluctuate wildly, ignoring macroeconomic events and general market movements.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Lexeo Therapeutics
Lexeo Therapeutics, a company focused on gene therapy for cardiovascular and neurological diseases, operates at the forefront of science. Its weekly stock price is a direct response to the publication of clinical trial data, creating high volatility and dependence on scientific breakthroughs.
Weekly dynamics of market capitalization of the market segment - Dna
Biotech companies developing gene therapy, like Lexeo, are at the forefront of science. News in this field often impacts the entire industry. The chart below illustrates this general sentiment. It allows one to assess how promising the market perceives Lexeo's platform compared to competitors' technologies in this revolutionary field.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Lexeo Therapeutics is a biotech company developing gene therapy for rare genetic diseases. Its shares operate in the world of clinical trials. The chart below demonstrates how their performance depends solely on internal news, rather than on overall market movements.
Market capitalization of the company, segment and market as a whole
LXEO - Market capitalization of the company Lexeo Therapeutics
Lexeo Therapeutics' market capitalization reflects investors' bets on its gene therapy portfolio for rare cardiovascular and neurological diseases. The chart reflects the market's belief that its drugs, which target the genetic causes of these diseases, will offer revolutionary treatments. Its value is an estimate of its scientific potential and the size of its target markets.
LXEO - Share of the company's market capitalization Lexeo Therapeutics within the market segment - Dna
Lexeo Therapeutics is a gene therapy company focused on treating rare cardiovascular and neurological diseases. In the cutting-edge DNA medicine segment, its market share reflects the hopes for its scientific platform. The company's market share is essentially an estimate of the likelihood of success of its clinical programs, which could lead to revolutionary treatments.
Market capitalization of the market segment - Dna
Here's a chart reflecting the combined weight of the entire biotech sector specializing in gene therapy. For Lexeo Therapeutics, which focuses on treating rare diseases, this line is a sign of hope. The rising chart represents an influx of capital into technologies capable of correcting genetic errors, allowing the company to pursue its expensive research.
Market capitalization of all companies included in a broad market index - GURU.Markets
Lexeo Therapeutics is a company focused on gene therapy for cardiovascular and neurological diseases. Its market capitalization is a bet on the possibility of "correcting" the genetic causes of heart and brain diseases. Within the overall market, this represents a fraction of the hope for a breakthrough in these areas.
Book value capitalization of the company, segment and market as a whole
LXEO - Book value capitalization of the company Lexeo Therapeutics
Lexeo Therapeutics is a company focused on gene therapy for cardiovascular and neurological diseases. Its book value is its financial resources for R&D. It consists of cash that allows it to conduct clinical trials. How has this vital capital changed? The chart below shows.
LXEO - Share of the company's book capitalization Lexeo Therapeutics within the market segment - Dna
Lexeo Therapeutics is a gene therapy company focused on cardiovascular diseases. Its cutting-edge science requires a substantial resource base: R&D centers and investment in manufacturing capacity to develop its drugs. The chart shows its share of the physical infrastructure needed to develop this complex class of drugs.
Market segment balance sheet capitalization - Dna
Lexeo Therapeutics, a gene therapy company, has a capital-intensive R&D business. This requires the ownership of cutting-edge laboratories. The BCap_Seg chart for the biotech sector shows that creating breakthrough technologies requires a robust scientific infrastructure, even before the manufacturing stage.
Book value of all companies included in the broad market index - GURU.Markets
Lexeo Therapeutics' balance sheet isn't its factories, but its scientific platform and portfolio of gene therapy programs for treating rare cardiovascular and neurological diseases. The company's assets are its intellectual capital. The chart shows how this science-intensive R&D asset compares to big pharma.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Lexeo Therapeutics
Lexeo's balance sheet is its R&D capital. Its entire market value is the premium paid for its gene therapy platform. Its price chart is investors' bet that its approach to treating rare diseases will be successful and approved by regulators.
Market to book capitalization ratio in a market segment - Dna
Lexeo Therapeutics is a gene therapy company focused on treating rare cardiovascular and neurological diseases. Its high valuation on this chart reflects its scientific platform and team's ability to bring complex drugs to market.
Market to book capitalization ratio for the market as a whole
Lexeo Therapeutics is a biotech company developing gene therapies for the treatment of cardiovascular and neurological diseases. Its market value is based on the potential of its research programs. Like many biotech companies, its valuation is a bet on a future medical breakthrough.
Debts of the company, segment and market as a whole
LXEO - Company debts Lexeo Therapeutics
Lexeo Therapeutics, a gene therapy company, is using capital to fund its clinical programs targeting rare genetic diseases of the heart and central nervous system. This chart shows how the biotech company is raising significant funds to advance its cutting-edge and potentially life-saving, but very expensive, research.
Market segment debts - Dna
Lexeo Therapeutics is a clinical-stage biotech company focused on gene therapy for cardiovascular and neurological diseases. Funding at this stage is entirely equity-based. This chart demonstrates the absence of significant debt, which is absolutely normal for a company operating at the cutting edge of science.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Lexeo Therapeutics
Lexeo Therapeutics is a gene therapy company, one of the most complex and expensive areas in modern medicine. This chart illustrates its total dependence on external funding for research. It is a prime example of the high financial risk investors are willing to bear for the sake of a potential breakthrough in disease treatment.
Market segment debt to market segment book capitalization - Dna
Lexeo Therapeutics is a gene therapy company focused on treating rare cardiovascular and neurological diseases. This is a cutting-edge, but very expensive, area of medicine. The chart shows how aggressively the biotech sector uses debt to fund R&D, and the conditions under which Lexeo is attempting to achieve breakthroughs.
Debt to book value of all companies in the market
Lexeo Therapeutics, a gene therapy company, is at the forefront of medical research, requiring massive, long-term capital investments. This chart, showing the overall market debt load, helps evaluate Lexeo's financial strategy. It highlights the company's risky approach to funding its breakthrough, yet-to-be-commercialized, technologies.
P/E of the company, segment and market as a whole
P/E - Lexeo Therapeutics
Lexeo Therapeutics is a clinical-stage biotech company developing gene therapies for the treatment of rare genetic cardiovascular and neurological diseases. This chart shows how the market values its scientific potential. This value is based on research success and the hope of a breakthrough in the treatment of these serious diseases.
P/E of the market segment - Dna
Lexeo Therapeutics is developing gene therapy. This chart shows the average valuation for the biotech sector. It emphasizes that Lexeo is valued not by current revenue, but by the potential of its scientific platform to treat rare diseases, which the market can value at a significant premium.
P/E of the market as a whole
Lexeo Therapeutics is a biopharmaceutical company developing gene therapies for the treatment of rare genetic diseases of the heart and central nervous system. This chart reflects the overall risk appetite of investors in biotech. It helps us understand whether Lexeo's high valuation is based on faith in its breakthrough scientific platform or is driven by overall sector sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Lexeo Therapeutics
Lexeo Therapeutics is a company focused on gene therapy for rare cardiovascular and neurological diseases. Future profits depend on the success of its high-tech clinical programs. This chart reflects investor expectations for scientific breakthroughs and the development of treatments for previously incurable diseases.
%20P%2FE%20Lexeo%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Lexeo-Therapeutics&v=1772616476028 "Chart of the company's future (projected) P/E Lexeo Therapeutics")
Future (projected) P/E of the market segment - Dna
Lexeo Therapeutics specializes in gene therapy for rare genetic diseases of the heart and central nervous system. The data here reflects the analysts' collective bets on the success of its clinical programs in these complex areas. It's a barometer of hope that its drugs will transform patients' lives.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772616476039 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Lexeo Therapeutics is developing gene therapies to treat rare cardiovascular and neurological diseases. This sentiment chart shows how willing investors are to fund cutting-edge science. Lexeo's success could change patients' lives, but it requires long-term capital and faith in their platform.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772616476045 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Lexeo Therapeutics
Lexeo Therapeutics is a gene therapy company focused on treating rare cardiovascular and neurological diseases. This chart highlights the high cost of cutting-edge medical research. It reflects investments in clinical programs that could offer gene therapy solutions for previously incurable diseases.
Profit of companies in the market segment - Dna
Lexeo Therapeutics is a clinical-stage biopharmaceutical company specializing in gene therapy for rare cardiovascular and neurological diseases. Its future profitability depends on success in this cutting-edge and complex area of medicine, reflecting the potential of gene therapy to transform patients' lives.
Overall market profit
Lexeo Therapeutics is a company specializing in gene therapy for rare cardiovascular and neurological diseases. Its value and future depend on the success of clinical trials. The overall economic situation, reflected in this chart, impacts financial markets and the availability of capital, which is vital for conducting lengthy and expensive research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Lexeo Therapeutics
Lexeo Therapeutics is a clinical-stage gene therapy company targeting inherited cardiac and CNS diseases. This chart shows analysts' speculative expectations. Future profits are entirely dependent on the success of clinical trials and potential approval of their cutting-edge treatments.
%20profit%20of%20the%20company%20Lexeo%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Lexeo-Therapeutics&v=1772616476108 "Graph of future (projected) profit of the company Lexeo Therapeutics")
Future (predicted) profit of companies in the market segment - Dna
Lexeo Therapeutics is a biotech company at the forefront of gene therapy, focusing on the treatment of rare cardiovascular and neurological diseases. The profitability projections for this sector, shown in the graph, reflect the enormous potential for breakthroughs. This chart helps assess how Lexeo's technology can transform patients' lives.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772616476148 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
Lexeo Therapeutics is a biotechnology company specializing in gene therapy for rare genetic diseases. Developing such complex treatments requires significant investment. The availability of capital for breakthrough but risky projects is highly dependent on overall investor risk appetite, which is growing amid positive economic forecasts.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772616476187 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Lexeo Therapeutics
Lexeo Therapeutics is a gene therapy company focused on treating inherited cardiovascular and neurological diseases. It has no commercial revenue. This chart illustrates the enormous value investors place on its research portfolio, betting on the development of breakthrough treatments.
P/S market segment - Dna
Lexeo Therapeutics is a clinical-stage company specializing in gene therapy for rare genetic cardiovascular and neurological diseases. This chart shows the average revenue estimate in the biotech sector. It helps understand the market premium for developments targeting high-potential orphan diseases.
P/S of the market as a whole
Lexeo Therapeutics is a clinical-stage gene therapy company focused on treating rare cardiovascular and neurological diseases. This chart compares how the market values companies based on current revenue, which is important for contextualizing biotech companies focused on developing treatments for previously incurable diseases.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Lexeo Therapeutics
Lexeo Therapeutics is a gene therapy company focused on treating inherited cardiac and central nervous system diseases. This chart reflects investors' high valuation of its potential future revenue. This valuation is a bet on the success of its clinical programs and the breakthrough potential of its therapeutic approaches.
%20P%2FS%20Lexeo%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Lexeo-Therapeutics&v=1772616476220 "The graph of the company's future (projected) P/S Lexeo Therapeutics")
Future (projected) P/S of the market segment - Dna
Lexeo Therapeutics is a clinical-stage company focused on gene therapy for cardiovascular and neurological diseases. This chart compares market expectations for its future revenue with other companies in the DNA technology sector. The valuation reflects investor confidence in the potential of its programs to treat inherited diseases.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772616476247 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
Lexeo Therapeutics is a clinical-stage biotechnology company specializing in gene therapy for rare genetic diseases of the heart and central nervous system. Its value depends on the success of its scientific developments. This chart of overall economic expectations for Lexeo is merely a backdrop, while its value is driven by scientific breakthroughs.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772616476323 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Lexeo Therapeutics
This chart shows the revenue of Lexeo Therapeutics, a company developing gene therapy for rare cardiovascular and neurological diseases. Being in the clinical stage, it has no commercial products and, therefore, no sales revenue. The chart with zero figures is typical and emphasizes the company's focus on science and clinical trials.
Sales of companies in the market segment - Dna
Lexeo Therapeutics is a clinical-stage biopharmaceutical company specializing in gene therapy for rare genetic diseases of the heart and central nervous system. This chart shows revenue in the DNA therapy sector. It reflects scientific progress and the hopes associated with the possibility of a one-time treatment for devastating inherited diseases.
Overall market sales
Lexeo Therapeutics is a gene therapy company for the treatment of inherited cardiovascular and neurological diseases. Its value is determined by success in clinical development. The overall economic situation shown in this chart does not affect the scientific process, but it does provide a backdrop for attracting investment in the biotech sector.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Lexeo Therapeutics
Lexeo Therapeutics is a clinical-stage gene therapy company focused on treating rare genetic diseases of the heart and central nervous system. This revenue projection is speculative. Its dynamics reflect analysts' confidence in the scientific potential of its drug candidates and the likelihood of their successful advancement through clinical development.
%20sales%20of%20the%20company%20Lexeo%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Lexeo-Therapeutics&v=1772616476349 "Schedule of future (projected) sales of the company Lexeo Therapeutics")
Future (projected) sales of companies in the market segment - Dna
Lexeo Therapeutics is a clinical-stage gene therapy company focused on treating rare cardiovascular and neurological diseases caused by single-gene mutations. This chart shows projected revenue for the entire DNA therapy sector, reflecting the potential for a single treatment that could correct the underlying cause of the disease.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772616476354 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
Lexeo Therapeutics is a gene therapy company developing treatments for cardiovascular and neurological diseases. Its future depends on success in clinical trials. The positive economic environment and growing markets are creating a favorable environment for attracting the investment vital for such capital-intensive and breakthrough research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772616476366 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Lexeo Therapeutics
Lexeo Therapeutics is a gene therapy company focused on rare cardiovascular and neurological diseases. It is in clinical development. This chart illustrates the financial side of cutting-edge science, showing the company's investment in testing potentially life-saving drugs.
Market segment marginality - Dna
Lexeo Therapeutics is a clinical-stage biotech company specializing in gene therapy for rare cardiovascular and neurological diseases. This chart reflects its operational efficiency. For a company operating at the cutting edge of science, this comparison with the sector demonstrates how effectively it manages its significant R&D expenditures.
Market marginality as a whole
Lexeo Therapeutics is a biotech company specializing in gene therapy for rare cardiovascular and neurological diseases. Its success is determined not by economic cycles, but by scientific breakthroughs and clinical trial results. The potential for developing treatments for previously incurable diseases is enormous.
Employees in the company, segment and market as a whole
Number of employees in the company Lexeo Therapeutics
Lexeo Therapeutics is a clinical-stage biotech company specializing in gene therapy for cardiovascular and neurological diseases. This chart shows its growing team of scientists. The increase in staff directly reflects the progress of its clinical programs and the complexity of gene therapy development and manufacturing.
Share of the company's employees Lexeo Therapeutics within the market segment - Dna
Lexeo Therapeutics is a biotech company specializing in gene therapy for cardiovascular and neurological diseases. Its team consists of a small group of leading scientists. This graph illustrates its focus on R&D: its minimal staff means its value lies in cutting-edge science, not operational scale.
Number of employees in the market segment - Dna
Lexeo Therapeutics is a gene therapy company focused on treating inherited cardiovascular diseases. This chart shows the cutting edge of cardiology. A small but growing team of scientists and clinicians reflects progress in clinical trials aimed at a one-time cure for severe genetic heart diseases.
Number of employees in the market as a whole
Lexeo Therapeutics is a biotech company specializing in gene therapy for rare genetic diseases of the heart and central nervous system. Its staff includes a team of leading scientists. This overall staffing chart highlights that at the forefront of science, growth is determined not by macroeconomics, but by the potential of technologies to change patients' lives and the investments attracted to achieve them.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Lexeo Therapeutics (LXEO)
Lexeo Therapeutics is a biotech company focused on gene therapy for cardiovascular and neurodegenerative diseases, particularly Alzheimer's. This chart shows the company's enormous market value per scientist, reflecting investors' belief that the company's revolutionary scientific approach can lead to breakthrough treatments.
%20of%20the%20company%20Lexeo%20Therapeutics%20(LXEO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Lexeo-Therapeutics-LXEO&v=1772616476428 "Chart of market capitalization per employee (in thousands of dollars) of the company Lexeo Therapeutics (LXEO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Lexeo Therapeutics is a biotech company specializing in gene therapy for rare cardiovascular and neurological diseases. In this cutting-edge field of medicine, this metric reflects investors' confidence in the future. The high market capitalization per employee suggests that the market highly values the potential of their platform for developing revolutionary treatments.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772616476434 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Lexeo Therapeutics develops gene therapy for rare genetic diseases. This metric clearly illustrates the biotech model: market capitalization reflects the potential value of its developments, not current revenue. This allows a small research team to enjoy a huge market valuation based on hope and cutting-edge science.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772616476443 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Lexeo Therapeutics (LXEO)
Lexeo Therapeutics is a clinical-stage biotech company specializing in gene therapy for cardiovascular and neurological diseases. They are not profitable. This chart shows the loss per employee. This is the cost of R&D in one of the most complex and expensive areas of modern medicine.
%20Chart%20Lexeo%20Therapeutics%20(LXEO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Lexeo-Therapeutics-LXEO&v=1772616476455 "Company Profit Per Employee (in thousands of dollars) Chart Lexeo Therapeutics (LXEO)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Lexeo Therapeutics is a biotech company working in gene therapy. The company has no profit, only R&D expenses. This is a cutting-edge and expensive field. This metric reflects R&D capital burn per employee, which is compared to industry standards for assessing the intensity of their research.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772616476457 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Lexeo Therapeutics is a biotech company specializing in gene therapy for cardiovascular and neurological diseases. This is cutting-edge, but very expensive R&D. This graph shows the negative value—the high cost of maintaining a team of elite scientists working on breakthrough DNA-based treatments.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772616476470 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Lexeo Therapeutics (LXEO)
Lexeo Therapeutics is a clinical-stage biotech company specializing in gene therapy for cardiovascular and neurological diseases. This schedule is typical for a biotech company in the R&D phase. No revenue per employee is normal, as all the value is in the development potential.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Lexeo-Therapeutics-LXEO&v=1772616476488 "Sales chart per company employee Lexeo Therapeutics (LXEO)")
Sales per employee in the market segment - Dna
Lexeo Therapeutics (LXEO) is a biotech company specializing in gene therapy for cardiovascular diseases and Alzheimer's disease. This chart shows how much revenue (from partnerships) each employee (scientist) generates. It's an indicator of the productivity of their R&D platform in some of the most complex yet widespread diseases.
Sales per employee for the market as a whole
Lexeo Therapeutics (LXEO) is a biopharmaceutical company specializing in gene therapy for rare cardiovascular and neurological diseases (such as Alzheimer's). This is an R&D business. The company has no commercial revenue, which does not yet reflect efficacy.
Short shares by company, segment and market as a whole
Shares shorted by company Lexeo Therapeutics (LXEO)
Lexeo Therapeutics is a biotech company specializing in gene therapy for cardiovascular and neurological diseases. This chart shows bearish bets. Bears are betting on an extremely high risk of clinical trial failure, which is typical for advanced but unproven gene therapy platforms.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Lexeo-Therapeutics-LXEO&v=1772616476509 "Short Shares Chart for the Company Lexeo Therapeutics (LXEO)")
Shares shorted by market segment - Dna
Lexeo Therapeutics is a biotech company developing gene therapies for cardiovascular and neurological diseases. This chart shows bearish sentiment. The "shorts" here are betting that their gene therapy will not prove safe or effective in the clinic.
Shares shorted by the overall market
Lexeo Therapeutics is a biotech company focused on gene therapy for cardiovascular and neurological diseases. It's at the cutting edge of science. This chart illustrates the overall level of market fear. When panic mounts, investors are quick to sell the riskiest assets, which include revenue-depleted biotechs working on complex diseases.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Lexeo Therapeutics (LXEO)
Lexeo Therapeutics (LXEO) is a biotech company focused on gene therapy, focusing on treating rare cardiovascular and neurodegenerative diseases (such as Alzheimer's). This chart measures hype. It shows "overheated" (above 70) during positive R&D data, or "oversold" (below 30) during periods of anticipation and high uncertainty.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Lexeo-Therapeutics-LXEO&v=1772616476515 "RSI 14 indicator chart for the company's stock Lexeo Therapeutics (LXEO)")
RSI 14 Market Segment - Dna
Lexeo (LXEO) is a biotech company, a vector "engineer." Their platform (AAV) creates "improved" delivery systems for gene therapy (especially for the heart). The RSI_14_Seg for "Dna" (biotech) shows the overall sentiment in the sector. The chart helps us understand: is LXEO's volatility a function of their platform, or is the entire sector overheated?
RSI 14 for the overall market
Lexeo Therapeutics (LXEO) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast LXEO (Lexeo Therapeutics)
Lexeo Therapeutics is a biotech company developing gene therapies for rare cardiovascular and neurological diseases, including Alzheimer's. This chart shows the analysts' average 12-month forecast, representing their collective speculative bet on the success of this cutting-edge and sophisticated R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-LXEO-Lexeo-Therapeutics&v=1772616476547 "A chart showing analyst consensus forecasts for the expected stock price. LXEO (Lexeo Therapeutics)")
The difference between the consensus estimate and the actual stock price LXEO (Lexeo Therapeutics)
Lexeo Therapeutics is a biotech company developing one-and-done gene therapy for the treatment of severe diseases, including genetic forms of Alzheimer's. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their faith in their cutting-edge science.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-LXEO-Lexeo-Therapeutics&v=1772616476551 "A chart showing the difference between the consensus forecast and the actual stock price. LXEO (Lexeo Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Dna
Lexeo Therapeutics is a biotech company developing gene therapy (based on AAV viruses) for the treatment of rare cardiac and neurological diseases (Alzheimer's). This chart shows general expectations for the DNA technology sector. It reflects whether experts believe in the commercial success of this complex R&D platform.
Analysts' consensus forecast for the overall market share price
Lexeo Therapeutics is a biotech company specializing in developing gene therapies for rare cardiovascular and neurological diseases. This chart shows overall risk appetite. For Lexeo, working in one of the most advanced and expensive areas of medicine, overall market optimism is critical to attracting the capital needed to fund research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Lexeo Therapeutics
Lexeo Therapeutics is a clinical-stage biotech company specializing in gene therapy. They develop drugs to treat rare inherited diseases, primarily cardiac and neurological. This chart is a pure reflection of their science. Its dynamics depend entirely on their progress in clinical trials and the market's confidence in their R&D platform.
AKIMA Market Segment Index - Dna
Lexeo (LXEO) is a clinical-stage biotech and a pioneer in gene therapy, developing (AAV) drugs for rare, fatal genetic diseases (including APOE4-related Alzheimer's). This summary metric measures R&D. The graph shows the segment average. This benchmark: how does LXEO's breakthrough (R&D platform) model differentiate it from the average pharma company?
The AKIM Index for the overall market
Lexeo Therapeutics is a biotech company specializing in genetic medicine for the treatment of cardiovascular diseases and Alzheimer's disease. This chart, which reflects the market average, is an indicator of risk appetite. It provides a macro backdrop that is critical for assessing the prospects of this early-stage scientific platform.
